You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

177Lu-PSMA-617

Showing 1 - 25 of 524
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco

Not yet recruiting
  • Castrate Resistant Prostate Cancer
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Mar 1, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (177Lu-PSMA-617, PSMA-11)

No longer available
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 12, 2023

Patients With Metastatic Castration-resistant Prostate Cancer Trial (177Lu-PSMA-617 PET scan)

Not yet recruiting
  • Patients With Metastatic Castration-resistant Prostate Cancer
  • 177Lu-PSMA-617 PET scan
  • (no location specified)
Nov 13, 2023

Prostate Cancer Trial (AAA617)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
Mar 27, 2023

Prostate Cancer Trial in New York (177Lu-PSMA-617, Stereotactic Body Radiotherapy (SBRT))

Active, not recruiting
  • Prostate Cancer
  • 177Lu-PSMA-617
  • Stereotactic Body Radiotherapy (SBRT)
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Nov 17, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Cabozantinib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Nov 10, 2022

Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Melbourne (Cabazitaxel, 177Lu-PSMA-617)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • mCRPC
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Jul 20, 2022

Prostate Cancer Trial in Sapporo city, Kanazawa-city (177Lu-PSMA-617, 68Ga-PSMA-11, Best supportive/best standard of care)

Recruiting
  • Prostate Cancer
  • 177Lu-PSMA-617
  • +2 more
  • Kashiwa, Chiba, Japan
  • +6 more
Jan 23, 2023

Prostatic Tumor Trial (AAA617, AAA517, Piflufolastat F 18)

Not yet recruiting
  • Prostatic Neoplasm
  • (no location specified)
Apr 27, 2023

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in San

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +6 more
  • San Francisco, California
    University of California, San Francisco
Sep 8, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in San Francisco

Active, not recruiting
  • Castration Levels of Testosterone
  • +6 more
  • Lutetium Lu 177-PSMA-617
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Apr 11, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Seattle

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Biopsy
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Nov 17, 2023

Prostatic Tumors, Castration-Resistant Trial (64Cu-SAR-BBN, 67Cu-SAR-BBN)

Not yet recruiting
  • Prostatic Neoplasms
  • Castration-Resistant
  • (no location specified)
Dec 1, 2022

Metastatic Hormone Naive Prostate Cancer Trial in Australia (177Lu-PSMA-617, Docetaxel)

Recruiting
  • Metastatic Hormone Naive Prostate Cancer
  • Sydney, New South Wales, Australia
  • +4 more
Nov 4, 2022

Prostate Cancer Trial in New Orleans, New York (177Lu-PSMA-617, 68Ga-PSMA-HBED-CC)

Active, not recruiting
  • Prostate Cancer
  • New Orleans, Louisiana
  • +1 more
Nov 20, 2021

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 16, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, Best supportive/best standard of care

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 2, 2023

Prostate Cancer Trial in New York (177Lu-PSMA-617, 177Lu-J591, 68Ga-PSMA-HBED-CC)

Terminated
Has Results
  • Prostate Cancer
  • 177Lu-PSMA-617
  • +2 more
  • New York, New York
    Weill Cornell Medical College
Jul 29, 2021

Prostatic Tumors, Castration-Resistant Trial in Darlinghurst, Pretoria (225^Ac-PSMA-617, 68^Ga-PSMA-11)

Recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • 225^Ac-PSMA-617
  • 68^Ga-PSMA-11
  • Darlinghurst, Australia
  • +1 more
Nov 23, 2022

Prostate Cancer Trial in Vancouver, Montreal, Quebec City (177Lu-PSMA-617, Docetaxel)

Suspended
  • Prostate Cancer
  • Vancouver, British Columbia, Canada
  • +3 more
Jun 13, 2022

68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy

Enrolling by invitation
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Computed Tomography
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 16, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11GBq of 177Lu-EB-PSMA-617, 2.00 GBq of 177Lu-EB-PSMA-617,

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11GBq of 177Lu-EB-PSMA-617
  • +2 more
  • Beijing, China
    Peking Union Medical College Hospital
May 6, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 23, 2023

Oligometastatic Prostate Cancer (OMPC) Trial (AAA617)

Not yet recruiting
  • Oligometastatic Prostate Cancer (OMPC)
  • (no location specified)
Jul 3, 2023

Prostate Cancer Trial in Amsterdam, Groningen, Nijmegen (177Lu-PSMA-617)

Recruiting
  • Prostate Cancer
  • 177Lu-PSMA-617
  • Amsterdam, Netherlands
  • +3 more
Oct 17, 2021